Dara S. Ross, MD

Dara S. Ross, MD, of Memorial Sloan Kettering Cancer Center

Articles by Dara S. Ross, MD

Pedram Razavi, MD, PhD, breast medical oncologist, director, Liquid Biopsy & Genomics, Memorial Sloan Kettering Cancer Center; Dara S. Ross, MD, associate attending pathologist, Memorial Sloan Kettering Cancer Center

Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

ByPedram Razavi, MD, PhD,Dara S. Ross, MD

May 20th 2026

Drs Razavi and Ross note the evolution of ESR1 mutation–directed breast cancer management, including the role of genomic testing at metastatic recurrence.

Dara S. Ross, MD

Articles by Dara S. Ross, MD

Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

Latest Updated Articles

Trending on OncLive

FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma

Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC

ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care

Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD

Dr Borate on Efficacy Data for Shorter Venetoclax-Plus-Azacitidine Dosing in AML